Keyphrases
CD4 Count
50%
Clinical Outcomes
100%
Co-infection
16%
Corticosteroids
50%
COVID-19
50%
HIV Viral Load
16%
HIV-negative
16%
Hospitalized COVID-19 Patients
16%
Humanized
16%
IL-6 Blockade
100%
Interleukin
66%
Interleukin-6 Inhibitors
16%
Mechanical Ventilation
16%
Mortality Benefit
16%
Mortality Risk
16%
Overall Outcome
16%
Patients with COVID-19
100%
People Living with HIV (PLHIV)
100%
Sarilumab
16%
Secondary Infection
50%
Severe COVID-19
16%
Severely Ill
16%
Severely Ill Patients
16%
Tocilizumab
33%
Medicine and Dentistry
Artificial Respiration
11%
Case Presentation
11%
COVID-19
100%
Cytokine
44%
Human Immunodeficiency Virus
100%
Interleukin 6
100%
Interleukin 6 Receptor
11%
Mixed Infection
11%
Sarilumab
11%
Secondary Infection
33%
Tocilizumab
22%
Nursing and Health Professions
Artificial Respiration
11%
CD4 Lymphocyte Count
33%
Clinical Outcome
100%
Human Immunodeficiency Virus
100%
Interleukin 6
100%
Interleukin 6 Receptor
11%
Mixed Infection
11%
Sarilumab
11%
Secondary Infection
33%
Tocilizumab
22%
Virus Load
11%
Immunology and Microbiology
CD4 Lymphocyte Count
33%
Coinfection
11%
COVID-19
100%
Cytokine
44%
Human Immunodeficiency Virus
100%
Interleukin 6
100%
Interleukin-6 Receptor
11%
Sarilumab
11%
Tocilizumab
22%
Viral Load
11%
Pharmacology, Toxicology and Pharmaceutical Science
Cytokine
44%
HIV
100%
Interleukin 6
100%
Interleukin 6 Receptor
11%
Mixed Infection
11%
Sarilumab
11%
Secondary Infection
33%
Tocilizumab
22%
Biochemistry, Genetics and Molecular Biology
CD4 Lymphocyte Count
33%
Cytokine
44%
Human Immunodeficiency Virus
100%
Interleukin 6
100%
Interleukin-6 Receptor
11%
Virus Load
11%